NCT05415683

Brief Summary

During the observational, non-interventional study, at Baseline Study Visit (BSV) subjects will be screened and consented. Eligible subjects will undergo imaging with the DeepView device. Pre- and post-debridement images will be obtained (if debridement performed per SOC), as well as reviewing medical history and physical assessments. Additional Study Visits (SVs) will be performed when patient returns to the clinic for Routine Clinic Visit for up to 12 weeks or wound closure. During these visits DeepView imaging will occur pre- and post-debridement, and the status of the subject's treatment will be recorded.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Typical duration for all trials

Geographic Reach
1 country

11 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 13, 2022

Completed
9 days until next milestone

Study Start

First participant enrolled

June 22, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 28, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2024

Completed
Last Updated

November 8, 2024

Status Verified

November 1, 2024

Enrollment Period

2 years

First QC Date

June 8, 2022

Last Update Submit

November 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Data Collection

    The purpose of this study is to build a database for development and validation of a machine learning (ML) algorithm for diabetic foot ulcer (DFU) healing assessment using images obtained with the Spectral MD DeepView device.

    12 weeks

Study Arms (1)

Diabetic Foot Ulcer (DFU) Group

Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care

Diagnostic Test: DV-SSP Imaging

Interventions

DV-SSP ImagingDIAGNOSTIC_TEST

DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.

Diabetic Foot Ulcer (DFU) Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with DFUs undergoing SWC treatment

You may qualify if:

  • At least 18 years old.
  • Subject has an ulcer, or slow healing wound that is full thickness for at least 4 weeks, below the malleolus, in the presence of Diabetes.
  • The target ulcer will be the largest ulcer if two or more eligible DFUs are present and will be the only one evaluated in the study.
  • The target ulcer is planned to undergo standard wound care (SWC) therapy (See 8.6 Standard Wound Care (SWC) Therapy).
  • Subject understands and is willing to participate in the clinical study and can comply with required visits.

You may not qualify if:

  • Target ulcer is deemed by the investigator to be caused by a medical condition other than diabetes.
  • Target ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
  • Eligible DFU has associated untreated acute osteomyelitis or active infection
  • Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids \>10mg daily dose), or cytotoxic chemotherapy.
  • Subjects on any investigational drug(s) or device(s) within 30 days preceding initial study visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

Surgery of Foot and Ankle

Encino, California, 91316, United States

Location

New Hope Podiatry Group

Los Angeles, California, 90063, United States

Location

Northwell Hospital

Lake Success, New York, 11042, United States

Location

Cutting Edge Research LLC

Circleville, Ohio, 43920, United States

Location

Gentle Foot Care

Grove City, Ohio, 43123, United States

Location

Gentle Foot Care

Hilliard, Ohio, 43026, United States

Location

Foot and Ankle Specialist of Ohio

Mentor, Ohio, 44060, United States

Location

Worthington Foot and Ankle

Worthington, Ohio, 43085, United States

Location

Lower Extremity Institute of Research & Therapy (LEIRT)

Youngstown, Ohio, 44512, United States

Location

University of Tennessee Health Science Center, Wound Care Center @ Regional One

Memphis, Tennessee, 38103, United States

Location

West Houston Foot and Ankle

Missouri City, Texas, 77459, United States

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetic Foot

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetic Neuropathies

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2022

First Posted

June 13, 2022

Study Start

June 22, 2022

Primary Completion

June 28, 2024

Study Completion

August 30, 2024

Last Updated

November 8, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations